COMPARTIVE ANIMAL CORE

比较动物核心的总体目标是支持开发和使用本计划项目拨款中使用的动物模型。比较动物核心的指导原则是组织和肿瘤样本的有效规划和利用，处理和诊断的标准化，以及犬自发肿瘤动物模型的持续发展。该中心设在俄亥俄州立大学兽医学院的兽医生物科学系，并负责协调工作，其中包括在比较病理学、组织库以及临床试验开发和执行方面具有专业知识的人员。拟任命的核心董事谢丽尔·伦敦博士是一名董事会认证的兽医肿瘤学家，在抗癌药物开发方面拥有丰富的专业知识，包括验证新靶点、识别用于靶标抑制的适当小分子，以及在相关犬类癌症中测试这些化合物，目的是提供有助于人类药物开发过程的关键信息。共同研究人员Krista La Perie博士和Brad Bolon博士是兽医解剖病理学委员会认证，是比较病理学领域的专家，特别是关于癌症的小鼠模型和这些模型中的新疗法的评估。这一核心的主要目标是协助研究人员确定新的治疗方法在小鼠肉瘤模型中的毒性和活性，确定可能在临床环境中取得成功的候选药物/治疗方法，并评估这些治疗方法在患有自发性肉瘤的狗身上的作用，作为未来人类临床试验的前奏。因此，该核心的具体目标是：1)提供各种靶向疗法治疗后在小鼠疾病模型中产生的肉瘤的标准化组织病理学评估；2)确定与用新疗法治疗老鼠有关的不良反应。3)提供高质量的自发性肉瘤犬正常和肿瘤组织样本；4)评估新型STATS抑制剂(LY5)在正常犬和自发性骨肉瘤犬中的不良事件概况和生物活性。

The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics; 2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas; and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.